176 related articles for article (PubMed ID: 31802092)
21. Discovery of drug mode of action and drug repositioning from transcriptional responses.
Iorio F; Bosotti R; Scacheri E; Belcastro V; Mithbaokar P; Ferriero R; Murino L; Tagliaferri R; Brunetti-Pierri N; Isacchi A; di Bernardo D
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14621-6. PubMed ID: 20679242
[TBL] [Abstract][Full Text] [Related]
22. Drug Response Prediction by Globally Capturing Drug and Cell Line Information in a Heterogeneous Network.
Le DH; Pham VH
J Mol Biol; 2018 Sep; 430(18 Pt A):2993-3004. PubMed ID: 29966608
[TBL] [Abstract][Full Text] [Related]
23. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
24. Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.
Guo Y; Liang Z; Hou X; Zhang Z
Mol Med Rep; 2017 Oct; 16(4):4469-4474. PubMed ID: 28791417
[TBL] [Abstract][Full Text] [Related]
25. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.
Seifert M; Peitzsch C; Gorodetska I; Börner C; Klink B; Dubrovska A
PLoS Comput Biol; 2019 Nov; 15(11):e1007460. PubMed ID: 31682594
[TBL] [Abstract][Full Text] [Related]
26. Cancer network activity associated with therapeutic response and synergism.
Serra-Musach J; Mateo F; Capdevila-Busquets E; de Garibay GR; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Pérez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana MÀ
Genome Med; 2016 Aug; 8(1):88. PubMed ID: 27553366
[TBL] [Abstract][Full Text] [Related]
27. Mining Natural Products with Anticancer Biological Activity through a Systems Biology Approach.
Theofylaktou D; Takan I; Karakülah G; Biz GM; Zanni V; Pavlopoulou A; Georgakilas AG
Oxid Med Cell Longev; 2021; 2021():9993518. PubMed ID: 34422220
[TBL] [Abstract][Full Text] [Related]
28. CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.
Pu L; Singha M; Ramanujam J; Brylinski M
Oncotarget; 2022; 13():695-706. PubMed ID: 35601606
[TBL] [Abstract][Full Text] [Related]
29. A novel heterogeneous network-based method for drug response prediction in cancer cell lines.
Zhang F; Wang M; Xi J; Yang J; Li A
Sci Rep; 2018 Feb; 8(1):3355. PubMed ID: 29463808
[TBL] [Abstract][Full Text] [Related]
30. A link prediction approach to cancer drug sensitivity prediction.
Turki T; Wei Z
BMC Syst Biol; 2017 Oct; 11(Suppl 5):94. PubMed ID: 28984192
[TBL] [Abstract][Full Text] [Related]
31. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
[TBL] [Abstract][Full Text] [Related]
32. Sparse Partial Least Squares Methods for Joint Modular Pattern Discovery.
Chen J; Zhang S
Methods Mol Biol; 2020; 2082():173-186. PubMed ID: 31849015
[TBL] [Abstract][Full Text] [Related]
33. Gene module analysis of juvenile myelomonocytic leukemia and screening of anticancer drugs.
Zhao W; Wang L; Yu Y
Oncol Rep; 2018 Dec; 40(6):3155-3170. PubMed ID: 30272300
[TBL] [Abstract][Full Text] [Related]
34. Tissue-guided LASSO for prediction of clinical drug response using preclinical samples.
Huang EW; Bhope A; Lim J; Sinha S; Emad A
PLoS Comput Biol; 2020 Jan; 16(1):e1007607. PubMed ID: 31967990
[TBL] [Abstract][Full Text] [Related]
35. Identification of Disease-miRNA Networks Across Different Cancer Types Using SWIM.
Fiscon G; Conte F; Farina L; Pellegrini M; Russo F; Paci P
Methods Mol Biol; 2019; 1970():169-181. PubMed ID: 30963493
[TBL] [Abstract][Full Text] [Related]
36. Clinical drug response prediction from preclinical cancer cell lines by logistic matrix factorization approach.
Emdadi A; Eslahchi C
J Bioinform Comput Biol; 2022 Apr; 20(2):2150035. PubMed ID: 34923927
[TBL] [Abstract][Full Text] [Related]
37. DeepSynergy: predicting anti-cancer drug synergy with Deep Learning.
Preuer K; Lewis RPI; Hochreiter S; Bender A; Bulusu KC; Klambauer G
Bioinformatics; 2018 May; 34(9):1538-1546. PubMed ID: 29253077
[TBL] [Abstract][Full Text] [Related]
38. A tool for discovering drug sensitivity and gene expression associations in cancer cells.
Qin Y; Conley AP; Grimm EA; Roszik J
PLoS One; 2017; 12(4):e0176763. PubMed ID: 28453553
[TBL] [Abstract][Full Text] [Related]
39. A network flow-based method to predict anticancer drug sensitivity.
Qin Y; Chen M; Wang H; Zheng X
PLoS One; 2015; 10(5):e0127380. PubMed ID: 25992881
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of protein interactome networks prioritizes candidate genes with cancer signatures.
Li Y; Sahni N; Yi S
Oncotarget; 2016 Nov; 7(48):78841-78849. PubMed ID: 27791983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
